CN103491973B - 用于预防心血管疾病的婴儿配方产品 - Google Patents
用于预防心血管疾病的婴儿配方产品 Download PDFInfo
- Publication number
- CN103491973B CN103491973B CN201280019056.0A CN201280019056A CN103491973B CN 103491973 B CN103491973 B CN 103491973B CN 201280019056 A CN201280019056 A CN 201280019056A CN 103491973 B CN103491973 B CN 103491973B
- Authority
- CN
- China
- Prior art keywords
- infant formula
- protein
- formula product
- product
- source
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000013350 formula milk Nutrition 0.000 title claims abstract description 88
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract description 29
- 239000000203 mixture Substances 0.000 claims abstract description 50
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 42
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 42
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 13
- 150000002632 lipids Chemical class 0.000 claims abstract description 10
- 239000000047 product Substances 0.000 claims description 100
- 235000018102 proteins Nutrition 0.000 claims description 41
- 238000009472 formulation Methods 0.000 claims description 18
- 230000036772 blood pressure Effects 0.000 claims description 16
- 102000004407 Lactalbumin Human genes 0.000 claims description 14
- 108090000942 Lactalbumin Proteins 0.000 claims description 14
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 13
- 235000014633 carbohydrates Nutrition 0.000 claims description 12
- 230000007062 hydrolysis Effects 0.000 claims description 12
- 238000006460 hydrolysis reaction Methods 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- 210000000481 breast Anatomy 0.000 claims description 9
- 239000005018 casein Substances 0.000 claims description 6
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 6
- 235000021240 caseins Nutrition 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 102000014171 Milk Proteins Human genes 0.000 claims description 4
- 108010011756 Milk Proteins Proteins 0.000 claims description 4
- 230000000774 hypoallergenic effect Effects 0.000 claims description 4
- 235000021239 milk protein Nutrition 0.000 claims description 4
- 239000003531 protein hydrolysate Substances 0.000 claims description 4
- 235000021316 daily nutritional intake Nutrition 0.000 claims description 3
- 239000000413 hydrolysate Substances 0.000 claims description 3
- 235000013336 milk Nutrition 0.000 claims description 3
- 239000008267 milk Substances 0.000 claims description 3
- 210000004080 milk Anatomy 0.000 claims description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 2
- 108010009736 Protein Hydrolysates Proteins 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 abstract description 28
- 230000002265 prevention Effects 0.000 abstract description 5
- 238000000034 method Methods 0.000 description 12
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000035487 diastolic blood pressure Effects 0.000 description 9
- 235000019197 fats Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 229910052500 inorganic mineral Inorganic materials 0.000 description 8
- 239000011707 mineral Substances 0.000 description 8
- -1 Carbon water Compound Chemical class 0.000 description 7
- 230000003203 everyday effect Effects 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 229940088594 vitamin Drugs 0.000 description 7
- 229930003231 vitamin Natural products 0.000 description 7
- 235000013343 vitamin Nutrition 0.000 description 7
- 239000011782 vitamin Substances 0.000 description 7
- 201000010099 disease Diseases 0.000 description 6
- 150000003722 vitamin derivatives Chemical class 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 206010008190 Cerebrovascular accident Diseases 0.000 description 5
- 208000006011 Stroke Diseases 0.000 description 5
- 208000029078 coronary artery disease Diseases 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 206010019280 Heart failures Diseases 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 4
- 235000008452 baby food Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 4
- 210000002216 heart Anatomy 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 3
- 239000005862 Whey Substances 0.000 description 3
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000003995 emulsifying agent Substances 0.000 description 3
- 201000006370 kidney failure Diseases 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 230000000529 probiotic effect Effects 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 2
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 2
- 239000005642 Oleic acid Substances 0.000 description 2
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 2
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- 235000019485 Safflower oil Nutrition 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 229930003451 Vitamin B1 Natural products 0.000 description 2
- 229930003779 Vitamin B12 Natural products 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000021342 arachidonic acid Nutrition 0.000 description 2
- 229940114079 arachidonic acid Drugs 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000019577 caloric intake Nutrition 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- DVSZKTAMJJTWFG-UHFFFAOYSA-N docosa-2,4,6,8,10,12-hexaenoic acid Chemical compound CCCCCCCCCC=CC=CC=CC=CC=CC=CC(O)=O DVSZKTAMJJTWFG-UHFFFAOYSA-N 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 230000008753 endothelial function Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000021323 fish oil Nutrition 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 229960000304 folic acid Drugs 0.000 description 2
- 235000019152 folic acid Nutrition 0.000 description 2
- 239000011724 folic acid Substances 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 201000009939 hypertensive encephalopathy Diseases 0.000 description 2
- 235000021125 infant nutrition Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 229960003512 nicotinic acid Drugs 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 229940055726 pantothenic acid Drugs 0.000 description 2
- 235000019161 pantothenic acid Nutrition 0.000 description 2
- 239000011713 pantothenic acid Substances 0.000 description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 239000003813 safflower oil Substances 0.000 description 2
- 235000005713 safflower oil Nutrition 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 229960003495 thiamine Drugs 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000010374 vitamin B1 Nutrition 0.000 description 2
- 239000011691 vitamin B1 Substances 0.000 description 2
- 235000019163 vitamin B12 Nutrition 0.000 description 2
- 239000011715 vitamin B12 Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 239000011726 vitamin B6 Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- DWNBOPVKNPVNQG-LURJTMIESA-N (2s)-4-hydroxy-2-(propylamino)butanoic acid Chemical compound CCCN[C@H](C(O)=O)CCO DWNBOPVKNPVNQG-LURJTMIESA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 102000010445 Lactoferrin Human genes 0.000 description 1
- 108010063045 Lactoferrin Proteins 0.000 description 1
- 102000008192 Lactoglobulins Human genes 0.000 description 1
- 108010060630 Lactoglobulins Proteins 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- ABSPRNADVQNDOU-UHFFFAOYSA-N Menaquinone 1 Natural products C1=CC=C2C(=O)C(CC=C(C)C)=C(C)C(=O)C2=C1 ABSPRNADVQNDOU-UHFFFAOYSA-N 0.000 description 1
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 1
- 201000010859 Milk allergy Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 201000002451 Overnutrition Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 201000004239 Secondary hypertension Diseases 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- MNCUCCJMXIWMJJ-OWOJBTEDSA-N [(e)-2-thiocyanatoethenyl] thiocyanate Chemical compound N#CS\C=C\SC#N MNCUCCJMXIWMJJ-OWOJBTEDSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000002302 brachial artery Anatomy 0.000 description 1
- 235000020246 buffalo milk Nutrition 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 235000020248 camel milk Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 150000005690 diesters Chemical class 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 206010061989 glomerulosclerosis Diseases 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 235000020251 goat milk Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000010247 heart contraction Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 235000020252 horse milk Nutrition 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 235000021242 lactoferrin Nutrition 0.000 description 1
- 229940078795 lactoferrin Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 210000000885 nephron Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 1
- 235000020665 omega-6 fatty acid Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000019175 phylloquinone Nutrition 0.000 description 1
- 239000011772 phylloquinone Substances 0.000 description 1
- MBWXNTAXLNYFJB-NKFFZRIASA-N phylloquinone Chemical compound C1=CC=C2C(=O)C(C/C=C(C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C)=C(C)C(=O)C2=C1 MBWXNTAXLNYFJB-NKFFZRIASA-N 0.000 description 1
- 229960001898 phytomenadione Drugs 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000009862 primary prevention Effects 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 235000020254 sheep milk Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000012859 sterile filling Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 208000020854 vein disease Diseases 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 235000021119 whey protein Nutrition 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000021241 α-lactalbumin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
- A23L33/155—Vitamins A or D
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/19—Dairy proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
- A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Pediatric Medicine (AREA)
- Botany (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
用于预防心血管疾病、特别是用于预防与高血压有关的心血管疾病的婴儿配方产品,其包含至少一种蛋白质源、脂质源、碳水化合物源,其中的蛋白质含量低于2.1g/100kcal。优选所述组合物是一阶段婴儿配方产品。
Description
发明领域
本发明涉及用于预防心血管疾病和预防高血压、尤其是生命后期的心血管疾病和高血压的婴儿配方产品,优选一阶段婴儿配方产品。
发明背景
血压是当心脏泵出血液时血液施加给动脉壁的压力。如果该压力升高并且长时间保持很高,其将会以多种方式对身体造成损害。
血压计数包括收缩压和舒张压。收缩压是心脏收缩并泵出血液时的压力。舒张压是当心脏处于两次收缩间期时的血压。
高血压是一种严重的情况,其伴随着心血管疾病的高风险,并且可导致例如冠心病、心衰、中风、肾衰以及其它心脏问题。就心血管疾病而言,存在高血压作为其症状或病因之一的那些心血管疾病是特别令人关注的。
高血压是一种由持续的高血压造成的疾病状况。高血压是一种系统动脉压超出正常范围的心脏的慢性医学状况。高血压通常是指其中的收缩压为140mmHg或更高或舒张压为90mmHg或更高的情况。高血压分为原发性的或继发性的。约90–95%的病例被称为“原发性高血压”,它是指医学原因不明的高血压。剩余5–10%的病例(继发性高血压)是由影响肾、动脉、心脏或内分泌系统的其它病症造成的。
高血压在世界范围内的发病率正在增加。此外,高血压可能会引起致命的并发症例如脑卒中、心衰和冠状动脉疾病,甚至是在不显示外部症状的轻或中度患者中。
有一些因素与高血压有关,包括成人期的体重和饮食,但作用于生命最初时期的环境影响、包括婴儿营养也会影响将来的血压。例如,Boubred等人(2007)证实,在大鼠中,出生后早期过度喂养提高了出生后肾发育,但在雄性的成年大鼠中观察到了血压升高以及肾小球硬化。Jarvisalo等人(2009)得出结论,与采用配方奶喂养的男性相比,母乳喂养的成年男性具有更好的肱动脉内皮功能。
就婴儿营养而言,人类母乳代表了无可争议的金标准。但是,由于医学的原因或是由于母亲不选择母乳喂养,母乳喂养在某些情况下是不够或不成功的。针对这些情况,开发了婴儿配方产品。
WO2010/070613A2涉及婴儿喂养配方产品以及相关的系统。更具体地讲,其公开了用于早产婴儿的具有低蛋白含量(低于1g/100mL)和低能量含量(低于50kcal/100mL)的婴儿配方产品。其中没有提供关于血压的数据。
WO2007/004878A2涉及治疗和/或预防儿童肥胖的方法,其包括施用一种包含脂肪、可消化的碳水化合物和蛋白质的营养组合物,其中的蛋白质包含以蛋白质的干重计至少25%重量的链长为25至30个氨基酸的肽。其中公开了胰岛素的分泌降低。
WO2006/069918A1涉及具有降低的蛋白质含量的婴儿配方产品用于在婴儿出生后的最初几个月中连续降低IGF-1的循环水平的用途。
EP1932437A1涉及用于在生命后期有出现肥胖风险的婴儿的婴儿配方产品,其能量密度低于650kcal/升,蛋白质含量低于1.8g/100kcal。其中没有提到血压。
在一篇题为“FrühkindlicheundAdipositasrisiko”的综述性文章(Bundesgesundheitsbl.2010,53:666-673)中,Koletzko等人讨论了低蛋白配方产品对于降低肥胖风险的潜在益处。
因此,需要可用于预防生命后期的心血管疾病或高血压的婴儿配方产品。
发明概述
因此,本发明提供了一种用于预防尤其是生命后期的心血管疾病或高血压的婴儿配方产品,其包含至少一种蛋白质源、脂质源、碳水化合物源,其中蛋白质含量低于2.1g/100kcal。
本发明的另一方面涉及预防患者的心血管疾病的方法,包括在患者出生后的至少三个月且不超过一年的时间内向所述患者喂食婴儿配方产品,其中所述婴儿配方产品包含至少一种蛋白质源、脂质源、碳水化合物源,并且其中婴儿配方产品的蛋白质含量低于2.1g/100kcal。
本发明的又一方面涉及预防患者的高血压的方法,包括在自患者出生起一年内,在至少三个月的时期内给所述患者喂食婴儿配方产品,其中所述婴儿配方产品包含至少一种蛋白质源、脂质源、碳水化合物源,并且其中婴儿配方产品的蛋白质含量低于2.1g/100kcal。
发明人令人惊奇地发现,本发明所用的婴儿配方产品对于预防高血压、并且潜在地对于预防心血管疾病、特别是与高血压有关的心血管疾病是特别有利的。所述疾病包括冠心病、心衰、外周动脉疾病、高血压性视网膜病、高血压性脑病、中风和肾衰竭。预防效果可以在生命后期、例如最早在3岁时观察到,尽管只是在婴儿时向该患者喂食了婴儿配方产品。
发明详述
本文所用的下列术语具有如下含义。
术语“婴儿”是指年龄不到12个月的儿童。
术语“婴儿配方产品”意指预期用于一岁以内的婴儿的特定营养用途、且本身满足此类人的营养要求的食品(参见1991年5月14日的欧洲委员会指令(European CommissionDirective)91/321/EEC的定义)。术语“婴儿配方产品”包括低过敏性婴儿配方产品。术语“婴儿配方产品”包括一阶段婴儿配方产品和后续配方产品。
术语“一阶段婴儿配方产品”意指预期用于在生命前四至六个月期间的婴儿的特定营养用途的食品。
术语“后续配方产品”意指预期用于年龄在四至六个月、最大为12个月的婴儿的特定营养用途、且构成此类人的逐渐多样化饮食的主要液体元素的食品。
术语“预防心血管疾病”意指预防和降低心血管疾病的频率和/或发生率和/或严重程度和/或持续时间,通常是在生命后期。发生率涉及任何心血管疾病的次数。风险涉及出现心血管疾病的可能性。频率涉及同一心血管疾病的次数。持续时间涉及心血管疾病的总的持续时间。心血管疾病尤其是指与高血压有关的那些疾病。心血管疾病包括例如,冠心病、心衰、外周动脉疾病、高血压性视网膜病、高血压性脑病、中风和肾衰竭。根据人群统计的结果,据估计舒张压降低2mm Hg可使中风的风险降低15%,使冠心病的风险降低6%(CookNR,Cohen J,Hebert P,Taylor JO,Hennekens CH.Implications of small reductionsin diastolic blood pressure for primary prevention.Arch Intern Med..1995;155:701–709)。
术语“生命后期”包括终止干预之后的效果。“生命后期”可以是终止所述干预之后的数月或数年。因此,“生命后期”可以是指至少3岁大、十几岁或成人期。在幼儿的情况下,其是指2.5岁至10岁的年龄。在十几岁的情况下,其是指10至20岁的年龄。在成人的情况下,其是指大于18岁的年龄。更通常地讲,本发明的婴儿配方产品的使用在“生命后期”有作用。
除非另有说明,所有的百分比均是重量百分比。
根据本发明,婴儿配方产品优选用于预防与高血压有关的心血管疾病。换言之,高血压可以是所述心血管疾病的症状或病因之一。
优选地,配方产品的蛋白质含量在1.6至2.1g/100kcal的范围内。优选地,蛋白质含量低于2.0g/100kcal,更优选低于1.9g/100kcal,仍更优选低于1.85g/100kcal。例如,蛋白质含量在1.6至2.0g/100kcal的范围内,优选在1.6至1.9g/100kcal的范围内,更优选在1.6至1.85g/100kcal的范围内。
乳蛋白可以来源于牛奶、山羊奶、羊奶、水牛奶、骆驼奶、马奶及其混合物。
蛋白质源优选选自乳蛋白、乳蛋白部分水解物、低过敏性乳蛋白水解物及其混合物。蛋白质可以是完整的或水解的蛋白,或是完整的和水解的蛋白的混合物。优选地,一种婴儿配方产品的实例包含未水解的乳清蛋白。
在一个实施方案中,婴儿配方产品的蛋白质源可以基于乳清蛋白、酪蛋白及其混合物,以及基于大豆的蛋白质源。因此,蛋白质源包含乳清蛋白、酪蛋白或二者的混合物,并且更优选地,蛋白质源就是乳清蛋白、酪蛋白或二者的混合物。在一个优选的实施方案中,蛋白质源是乳清蛋白和酪蛋白的混合物,乳清蛋白/酪蛋白的比例至少等于50/50,优选至少等于60/40,更优选至少等于70/30。
就乳清蛋白而言,蛋白质源可基于酸乳清或甜乳清或其混合物,并且可以以任何需要的比例包含α-乳清蛋白和β-乳球蛋白。当婴儿配方产品包含乳清蛋白时,优选从乳清蛋白中除去大部分的酪蛋白-糖-大分子肽(CGMP),也就是说,CGMP的含量很低。优选地,相对于天然乳清蛋白,CGMP含量减少了至少80%。例如,蛋白质源可以包含水解的甜乳清级分,其中超过85%原始存在的CGMP被去除了,例如如EP1220620B1的实施例1所公开的。
提供部分水解的蛋白可能是有利的,例如对于确信有出现牛奶过敏的风险的婴儿而言。部分水解的蛋白是其中60-70%的蛋白质/肽群体的分子量低于1000道尔顿的组合物。部分水解的蛋白通常被认为是低过敏性的(HA)。乳蛋白水解物的水解程度可由NPN/TN%来表征。将非蛋白氮除以总氮广泛用作由酶水解产生的可溶性肽的量度。NPN/TN%意指非蛋白氮除以总氮X100。可如Adler-Nissen J-,1979,J.Agric.Food Chem.,27(6),1256-1262中详细描述的方法来测量NPN/TN%。通常,将部分水解的蛋白表征为NPN/TN%在75%-85%的范围内。优选地,蛋白水解物的NPN/TN%在70-90%、优选75至85%的范围内。
如果需要水解的蛋白,则可按照本领域已知的方法根据需要进行水解过程。例如,乳清蛋白水解物可以通过在一个或多个步骤中酶水解乳清级分来制备。如果用作起始材料的乳清级分基本不含乳糖,则发现在水解过程中蛋白质的赖氨酸阻断要少的多。这可以使赖氨酸阻断的程度从总赖氨酸的大约15wt%降低至少于赖氨酸的约10wt%;例如约7wt%的赖氨酸,这大大提高了蛋白质源的营养质量。可以加入游离的精氨酸、游离的组氨酸、游离的牛磺酸、游离的酪氨酸、富含色氨酸的乳蛋白、游离的色氨酸或它们的混合物。也可在婴儿配方产品中加入核苷酸以及肉碱作为氮源。
因此,蛋白质源可以包含乳清蛋白、酪蛋白、其水解物或其混合物。
适宜的碳水化合物源是乳糖、蔗糖、麦芽糊精、淀粉。可以使用它们的混合物。碳水化合物源优选包含乳糖。优选地,碳水化合物源包含至少80%的乳糖,更优选至少90%乳糖,仍更优选至少95%乳糖。在一个优选的实施方案中,碳水化合物源就是乳糖本身。通常,当婴儿配方产品包含乳糖时,乳糖以9至13g/100kcal,优选10至12g/100kcal的量存在。
婴儿配方产品通常包含脂质源。在该情况下,脂质源可以是适用于婴儿配方产品的任何脂或脂肪。优选的脂肪源包括乳脂、红花油、蛋黄脂质、芥花籽油(Canola oil)、橄榄油、椰子油、棕榈仁油、大豆油、鱼油、棕榈油酸甘油酯(palm oleic)、高油酸葵花籽油和高油酸红花油,以及包含长链多不饱和脂肪酸的微生物发酵油。脂质源还可以是得自这些油的级分的形式,例如棕榈油(palm olein)、中链甘油三酯,以及脂肪酸例如花生四烯酸、亚油酸、棕榈酸、硬脂酸、二十二碳六烯酸、亚麻酸、油酸、月桂酸、癸酸、辛酸、己酸等的酯。还可以加入少量的包含大量预先形成的花生四烯酸和二十二碳六烯酸的油,例如鱼油或微生物油。优选脂肪源中n-6脂肪酸与n-3脂肪酸的比例为约5:1至约15:1,例如约8:1至约10:1。
在一个实施方案中,婴儿配方产品的能量密度为600kcal/L至780kcal/L,优选630kcal/L至700kcal/L。
该婴儿配方产品还优选以营养显著量包含认为对于日常饮食必需的所有维生素和矿物质。已经确定了对某些维生素和矿物质的最低需求量。任选地存在于婴儿配方产品中的矿物质、维生素和其他营养物质的例子包括维生素A、维生素B1、维生素B2、维生素B6、维生素B12、维生素E、维生素K、维生素C、维生素D、叶酸、肌醇、烟酸、生物素、泛酸、胆碱、钙、磷、碘、铁、镁、铜、锌、锰、氯、钾、钠、硒、铬、钼、牛磺酸和L-肉碱。矿物质通常以盐的形式加入。特定矿物质和其他维生素的存在和量将根据所针对的人群而改变。
根据需要,该婴儿配方产品可包含乳化剂和稳定剂,例如大豆卵磷脂、柠檬酸的甘油单酯和二酯等。
该婴儿配方产品还可包含至少一种益生菌。优选的益生菌是那些作为整体是安全的益生菌,是能够产生L(+)乳酸的培养物并且对于产品例如婴儿配方产品和后续配方产品(这些产品要求能够保持稳定和有效达36个月)具有可接受的保存期。
该婴儿配方产品优选具有低于标准的婴儿配方产品和后续配方产品的电解质水平。例如,NA/K比值(mmol)可以为约0.4,(Na+K)/Cl比值(mmol)可以为约1.8,Na+K+Cl可以为约34(mmol),(Na+K)-Cl可以为约10(mmol)。该婴儿配方产品优选具有低的磷酸盐/酯含量,并且优选磷含量低于40mg/100kcal。优选地,该婴儿配方产品的钙含量在35至45g/100mL之间,磷含量在15至25mg/mL之间,并且Ca/P比值在1.4至3之间。
该婴儿配方产品还可包含具有有益效果的其他物质,例如乳铁蛋白、纤维素、核苷酸、核苷等。
所有上述的用途是特别针对婴儿和幼儿的,特别是0至36个月大婴儿和幼儿。具体地讲,上述婴儿配方产品和应用适于有心血管疾病风险的婴儿,特别是有心血管疾病家族史的婴儿。更具体地讲,上述婴儿配方产品和应用适于有与高血压有关的心血管疾病、即其中高血压是其症状或病因之一的心血管疾病的风险的婴儿。
该婴儿配方产品可以是一阶段婴儿配方产品或后续配方产品,优选该组合物为一阶段婴儿配方产品。用于本发明用途的婴儿配方产品是用于以液体组合物的形式给婴儿食用的。然而,婴儿配方产品也可以以粉末婴儿配方产品的形式提供,其可以通过将粉末婴儿配方产品与水混合而复溶为液体形式。
该婴儿配方产品的剂量方案可以根据三项参数来设计,这三项参数可以组合在一起并且具体如下所述:
-婴儿配方产品在每日食物摄取量中所占的水平,
-方案的持续时间,
-方案的起始日期。
在本说明书中,食物摄取是以能量摄取来评估的。
优选地,婴儿配方产品应占婴儿每日食物(或能量)摄取量的至少50%,更优选占婴儿每日食物(或能量)摄取量的至少60%或甚至至少70%。在另一个优选的实施方案中,婴儿配方产品占婴儿每日食物(或能量)摄取量的至少80%。优选地,婴儿配方产品占婴儿食物(或能量)摄取量的全部。
该剂量方案优选在自婴儿出生起的一年内持续至少3个月。该方案可以持续3个月以上,例如至少6个月,甚至可以长达婴儿配方产品对于该年龄段是适宜的食品为止。例如,该方案可以自出生起维持长达3至6个月,或者甚至长达9或12个月。优选地,该方案自婴儿出生时开始(包括早产儿),在自出生起一年内结束。该方案可以在婴儿期内变化。在出生后的前4至6个月内,婴儿配方产品可以是一阶段配方产品,并且可以占该时期内婴儿食物(或能量)摄取量的全部。一旦开始食物多样化,婴儿配方产品就可以采用后续配方产品。其在婴儿食物(或能量)摄取量中所占的比例减少,例如为每日食物(或能量)摄取量的30%、40%或50%,最多达90%、80%或70%,这取决于给予婴儿的非配方食物的量。通常,非配方食物的量随着时间而增加。
例如,在自出生起一年内,在至少3个月至6个月的时期内,婴儿配方产品占每日食物(或能量)摄取量的至少50%。优选地,在婴儿生命的最初3个月至最初6个月的时期内(即出生后的前3至6个月内),婴儿配方产品占婴儿每日食物(或能量)摄取量的至少50%。更优选地,在婴儿生命的至少最初3个月至最初6个月的时期内,婴儿配方产品占婴儿每日食物(或能量)摄取量的至少80%。在又一种方案中,在婴儿生命的至少最初3个月的时期内,婴儿配方产品占婴儿食物(或能量)摄取量的全部。
本发明还涉及预防患者的心血管疾病的方法,或预防患者的高血压的方法。所述方法包括在自患者出生起一年内,在至少3个月的时期内给患者喂食婴儿配方产品,其中所述婴儿配方产品包含至少一种蛋白质源、脂质源、碳水化合物源,并且其中婴儿配方产品的蛋白质含量低于2.1g/100kcal。在上文中公开了用于这些方法的婴儿配方产品以及可以采用的多种剂量方案。
应当注意的是,该特定方案在患者年龄非常小的时候采用,优选自患者出生起的3至6个月内采用,直至12个月大。但是,预期的预防效果可以在患者的生命后期,例如在幼儿时期、在十几岁时或在成人时观察到。
在上述方法的一个优选的实施方案中,婴儿配方产品占患者每日食物(或能量)摄取量的至少50%。
现通过实施例的方式对可用于本发明的婴儿配方产品进行描述。
该配方产品可以以任何适宜的方式制备。例如,其可通过将蛋白质源、碳水化合物源以及脂肪源以适当的比例掺混在一起来制备。如需要可在此时加入乳化剂。可在此时加入维生素和矿物质,但通常在稍后加入以避免热降解。可在掺混之前将任何亲脂性维生素、乳化剂等溶解入脂肪源。然后可混入水、优选已进行过反渗透的水来形成液体混合物。水的温度优选在约50℃至约80℃的的范围内以促进各成分的分散。可以采用市售的液化剂来形成液体混合物。然后可将液体混合物例如分两个阶段均质化。
然后,可将液体混合物热处理以减少细菌载量,例如通过将液体混合物快速加热至约80℃至约150℃的温度,持续约5秒至约5分钟。这可通过蒸汽注射的方式、高压釜或换热器、例如板式换热器进行。
然后,可将液体混合物冷却至约60℃至约85℃,例如瞬时冷却。然后可再次均质化液体混合物,例如分两个阶段,在第一阶段约10MPa至约30MPa,在第二阶段约2MPa至约10MPa。然后可进一步冷却均质化的混合物以加入任何热敏成分,例如维生素和矿物质。此时方便地调节均质化混合物的pH和固体含量。
将均质化的混合物转移至合适的干燥装置如喷雾干燥器或冷冻干燥器中将其转变为粉末。所述粉末应当具有低于约5重量%的含水量。
如果优选液体婴儿配方产品,则可将均质化的混合物灭菌然后无菌灌装到适宜的容器中,或者也可先灌装到容器中然后再蒸煮灭菌。
结合附图(图1)可以容易地理解本发明的技术。附图1显示了采用三种不同的婴儿配方产品喂食(母乳喂养,BF;用于本发明的婴儿配方产品,F1.8;对比婴儿配方产品,F.2.8)的血压(BP)测量值(收缩压,SDP;舒张压,DBP;平均血压,MBP)。
将在以下实施例中对图1进行解释。
通过以下非限制性实施例对本发明进行进一步的阐释,给出这些实施例仅仅是为了举例说明的目的。
实施例
用于本发明的婴儿配方产品、即F1.8的组成如下表1所示(仅以举例说明的方式给出)。
表1
营养成分 | 每100kcal | 每升 |
能量(kcal) | 100 | 670 |
蛋白质(g) | 1.83 | 12.3 |
脂肪(g) | 5.3 | 35.7 |
亚油酸(g) | 0.79 | 5.3 |
α-亚麻酸(mg) | 101 | 675 |
乳糖(g) | 11.2 | 74.7 |
矿物质(g) | 0.37 | 2.5 |
Na(mg) | 23 | 150 |
K(mg) | 89 | 590 |
Cl(mg) | 64 | 430 |
Ca(mg) | 62 | 410 |
P(mg) | 31 | 210 |
Mg(mg) | 7 | 50 |
Mn(μg) | 8 | 50 |
Se(μg) | 2 | 13 |
维生素A(μg RE) | 105 | 700 |
维生素D(μg) | 1.5 | 10 |
维生素E(mg TE) | 0.8 | 5.4 |
维生素K1(μg) | 8 | 54 |
维生素C(mg) | 10 | 67 |
维生素B1(mg) | 0.07 | 0.47 |
维生素B2(mg) | 0.15 | 1.0 |
烟酸(mg) | 1 | 6.7 |
维生素B6(mg) | 0.075 | 0.50 |
叶酸(μg) | 9 | 60 |
泛酸(mg) | 0.45 | 3 |
维生素B12(μg) | 0.3 | 2 |
生物素(μg) | 2.2 | 15 |
胆碱(mg) | 10 | 67 |
Fe(mg) | 1.2 | 8 |
I(μg) | 15 | 100 |
Cu(mg) | 0.06 | 0.4 |
Zn(mg) | 0.75 | 5 |
采用包含2.7g蛋白/100kcal的配方产品(命名为F2.7)进行对比研究。两种婴儿配方产品F1.8和F2.7的能量均为670kcal/L。婴儿配方产品F1.8和F2.7的差别仅在于下表2中所示的成分:
表2
营养成分\组合物,每100kCal | F1.8 | F2.7 |
碳水化合(乳糖)(g) | 11.16 | 10.38 |
蛋白质(酪蛋白/乳清:30/70)(g) | 1.83 | 2.70 |
钠(mg) | 23 | 26 |
对碳水化合物水平进行调整以确保配方F1.8和F2.7的能量摄取水平相同。假定钠含量的差异与蛋白质含量的差异有关。认为钠含量差异的影响是可以忽略的。
在一项随机化的研究中,发明人测量了3岁儿童的舒张压、收缩压和平均血压,所述儿童在其出生后的最初4个月中仅采用如下之一进行喂食:
·母乳喂养(BF)(n=84);或
·本发明的低蛋白配方(1.8g蛋白质/100kcal)F1.8(n=74);或
·对比的高蛋白配方(2.7g蛋白质/100kcal)F2.8(n=80)。
母乳喂养和配方奶喂养的婴儿均可以在4个月时开始添加辅食。配方奶喂养的婴儿持续使用其各自的配方奶直至1岁,母乳喂养组接受低蛋白配方F1.8。根据例如婴儿的年龄,配方奶可以占婴儿食物摄取量的30至90%。
在下表3中概述了结果,并且在附图1中显示了所述结果。附图1显示了采用三种不同的婴儿配方产品喂食(母乳喂养,BF;用于本发明的婴儿配方产品,F1.8;对比婴儿配方产品,F.2.8)的血压(BP)测量值,即,收缩压,SDP;舒张压,DBP;平均血压,MBP。
表3
对于收缩压(SBP),F1.8与BF比,p=0.1849;F2.7与BF比,p=0.1377
对于舒张压(DBP),F1.8与BF比,p=0.0798;F2.7与BF比,p<0.04
对于平均血压(MBP),F1.8与BF比,p=0.0735;F2.7与BF比,p<0.01。
p值低于0.05表示差异是显著的。
因此,发明人证实,在其出生后的至少最初4个月内仅用低蛋白配方(1.8g蛋白质/100kcal)喂养的3岁的儿童,其血压值比那些仅用高蛋白配方(2.7g蛋白质/100kcal)喂养的儿童更接近母乳喂养的儿童。
参考文献
Boubred等人,(2007)。Effects of early postnatal hypernutrition onnephron number and long-term renal function and structure in rats.Am JPhysiol Renal Physiol,293:1944-1949。
Jarvisalo等人,(2009)。Breast feeding in infancy and arterialendothelial function later in life.European journal of clinical nutrition,63(5):640-645。
Claims (6)
1.包含至少一种蛋白质源、脂质源和碳水化合物源的婴儿配方产品在生产用于在婴儿出生后的至少最初4个月内仅用该产品喂养婴儿以使其血压更接近仅用母乳喂养的儿童的产品中的用途,其中蛋白质含量在1.6至1.85g/100kcal的范围内,其中的蛋白质是水解的,其中的蛋白质源是乳清蛋白和酪蛋白的混合物,并且乳清/酪蛋白的比例至少等于50/50,其中已从乳清蛋白中除去了大部分的酪蛋白-糖-大分子肽(CGMP),并且在自出生起的3至6个月内,所述配方产品占每日食物摄取量的至少50%。
2.权利要求1所述的用途,其中的蛋白质选自乳蛋白、乳蛋白部分水解物、低过敏性乳蛋白水解物及其混合物。
3.权利要求1和2任意一项所述的用途,其中的蛋白质源包含乳清蛋白、酪蛋白、它们的水解物或它们的混合物。
4.权利要求1至3任意一项所述的用途,其中的碳水化合物源包含乳糖。
5.权利要求4所述的用途,其中乳糖的含量范围是9至13g/100kcal。
6.权利要求1至5任意一项所述的用途,其中在自出生起一年内的至少三个月的时期内,所述配方产品占每日食物摄取量的至少50%。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11163011.7 | 2011-04-19 | ||
EP11163011A EP2514435A1 (en) | 2011-04-19 | 2011-04-19 | Infant formula for use in the prevention of cardiovascular diseases |
PCT/EP2012/057024 WO2012143362A1 (en) | 2011-04-19 | 2012-04-17 | Infant formula for use in the prevention of cardiovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103491973A CN103491973A (zh) | 2014-01-01 |
CN103491973B true CN103491973B (zh) | 2016-09-14 |
Family
ID=45953168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201280019056.0A Active CN103491973B (zh) | 2011-04-19 | 2012-04-17 | 用于预防心血管疾病的婴儿配方产品 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140044830A1 (zh) |
EP (2) | EP2514435A1 (zh) |
CN (1) | CN103491973B (zh) |
AU (1) | AU2012244798A1 (zh) |
BR (1) | BR112013026573A2 (zh) |
CA (1) | CA2831164A1 (zh) |
CL (1) | CL2013003003A1 (zh) |
IL (1) | IL228419A0 (zh) |
MX (1) | MX2013011833A (zh) |
RU (1) | RU2598707C2 (zh) |
SG (1) | SG193934A1 (zh) |
WO (1) | WO2012143362A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3366143A1 (en) | 2011-06-20 | 2018-08-29 | H.J. Heinz Company Brands LLC | Probiotic compositions and methods |
US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
US9345727B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
US10058116B2 (en) * | 2016-01-04 | 2018-08-28 | Cari Genea Crossley | Infant formula with improved nutritional value and digestive properties |
RU2643765C1 (ru) * | 2017-04-21 | 2018-02-05 | Федеральное государственное автономное учреждение "Национальный научно-практический центр здоровья детей" Министерства здравоохранения Российской Федерации (ФГАУ "ННПЦЗД" Минздрава России) | Способ оптимизации нутритивного статуса у детей первого полугодия жизни с хронической сердечной недостаточностью |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
CN113226465A (zh) * | 2018-12-19 | 2021-08-06 | 雀巢产品有限公司 | 用于预防或减少经皮水分流失并改善皮肤屏障功能的组合物 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887436A (en) * | 1956-05-28 | 1959-05-19 | Pfizer & Co C | Pharmaceutical compositions |
GB9923048D0 (en) | 1999-09-29 | 1999-12-01 | Nestle Sa | Composition comprising casein protein and whey protein |
AU765986B2 (en) * | 1999-04-29 | 2003-10-09 | Societe Des Produits Nestle S.A. | Composition for an infant formula having a low threonine content |
DE602004030567D1 (de) * | 2003-06-23 | 2011-01-27 | Nestec Sa | Säuglingsnährpräparat oder folgemilch |
EP1811865B1 (en) * | 2004-11-26 | 2008-07-16 | N.V. Nutricia | Infant nutrition with protease inhibitor |
US20100022451A1 (en) * | 2004-12-27 | 2010-01-28 | Nestec S.A. | Use of infant formula with reduced protein content |
PT1898724E (pt) * | 2005-07-01 | 2010-11-26 | Nutricia Nv | Nutrição infantil com proteínas hidrolisadas |
US20070166354A1 (en) * | 2005-10-26 | 2007-07-19 | Bridget Barrett-Reis | Method of reducing the risk of retinopathy of prematurity in preterm infants |
EP1962617A2 (en) * | 2005-12-23 | 2008-09-03 | N.V. Nutricia | Infant nutritional compositions for preventing obesity |
RU2445361C2 (ru) * | 2006-06-13 | 2012-03-20 | Нестек С.А. | Профилактика и лечение воспаления среднего уха с помощью непатогенных штаммов бактерий |
EP1974734A1 (en) * | 2007-03-28 | 2008-10-01 | Nestec S.A. | Probiotics for reduction of risk of obesity |
US8034394B2 (en) * | 2007-07-12 | 2011-10-11 | Michael Laurence Murphy | Hydroalcoholic fat emulsion and emulsifier for use therein |
MX348901B (es) * | 2007-11-26 | 2017-07-03 | Nestec Sa | Sistema nutricional adaptado a la edad para infantes. |
RU2478309C2 (ru) * | 2007-12-21 | 2013-04-10 | Н.В. Нютрисиа | Применение сфингомиелина и неперевариваемых углеводов для нормализации микробиоты кишечника |
US20090311367A1 (en) * | 2008-06-17 | 2009-12-17 | Perry Stephen C | Dietary Supplement |
MY160275A (en) * | 2008-09-02 | 2017-02-28 | Nutricia Nv | Nutritional compositions with lipid globules with a core comprising vegetable lipids and a coating comprising phospholipids or polar lipids |
WO2010070613A2 (en) * | 2008-12-18 | 2010-06-24 | University College London | Baby feeding formula and system |
CA2749254A1 (en) * | 2009-01-19 | 2010-07-22 | Catherine Mace | Nutritional composition for infants |
ES2570774T3 (es) * | 2009-04-01 | 2016-05-20 | Nestec Sa | Uso de ácido araquidónico para reducir el riesgo de resistencia a la insulina más adelante en la vida |
CA2755860A1 (en) * | 2009-04-03 | 2010-10-07 | Nestec S.A. | Improvement in promotion of healthy catch-up growth |
US9149452B2 (en) * | 2009-04-20 | 2015-10-06 | Women's & Children's Health Research Institute Inc. | Methods and compositions for promoting the neurological development of an infant |
-
2011
- 2011-04-19 EP EP11163011A patent/EP2514435A1/en not_active Withdrawn
-
2012
- 2012-04-17 BR BR112013026573A patent/BR112013026573A2/pt not_active IP Right Cessation
- 2012-04-17 EP EP12714027.5A patent/EP2699251B1/en active Active
- 2012-04-17 WO PCT/EP2012/057024 patent/WO2012143362A1/en active Application Filing
- 2012-04-17 AU AU2012244798A patent/AU2012244798A1/en not_active Abandoned
- 2012-04-17 CN CN201280019056.0A patent/CN103491973B/zh active Active
- 2012-04-17 SG SG2013071402A patent/SG193934A1/en unknown
- 2012-04-17 CA CA2831164A patent/CA2831164A1/en not_active Abandoned
- 2012-04-17 US US14/113,170 patent/US20140044830A1/en not_active Abandoned
- 2012-04-17 MX MX2013011833A patent/MX2013011833A/es unknown
- 2012-04-17 RU RU2013151165/15A patent/RU2598707C2/ru active
-
2013
- 2013-09-12 IL IL228419A patent/IL228419A0/en unknown
- 2013-10-16 CL CL2013003003A patent/CL2013003003A1/es unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1932437A1 (en) * | 2006-12-15 | 2008-06-18 | Nestec S.A. | Infant formula |
Also Published As
Publication number | Publication date |
---|---|
BR112013026573A2 (pt) | 2016-09-06 |
CN103491973A (zh) | 2014-01-01 |
WO2012143362A1 (en) | 2012-10-26 |
CL2013003003A1 (es) | 2014-04-21 |
US20140044830A1 (en) | 2014-02-13 |
EP2699251B1 (en) | 2017-03-22 |
EP2514435A1 (en) | 2012-10-24 |
AU2012244798A1 (en) | 2013-10-03 |
RU2598707C2 (ru) | 2016-09-27 |
EP2699251A1 (en) | 2014-02-26 |
IL228419A0 (en) | 2013-12-31 |
SG193934A1 (en) | 2013-11-29 |
RU2013151165A (ru) | 2015-05-27 |
CA2831164A1 (en) | 2012-10-26 |
MX2013011833A (es) | 2013-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103491973B (zh) | 用于预防心血管疾病的婴儿配方产品 | |
ES2837050T3 (es) | Composición nutricional líquida que comprende caseína micelar y proteína de suero de leche hidrolizada | |
CN101087539A (zh) | 蛋白质含量降低的婴儿配方的用途 | |
CN102231955A (zh) | 乳清蛋白组合物、方法及用途 | |
JP7165583B2 (ja) | コラーゲンを含む高カロリー、高タンパク質の栄養配合物 | |
MX2011003276A (es) | Composicion nutricional con propiedades anti-regurgitacion. | |
JP5384333B2 (ja) | ホエイタンパク質を高濃度で含む液状栄養組成物およびその製造方法 | |
US20240108050A1 (en) | Infant nutrition with hydrolysed protein, ionic calcium and palmitic acid | |
AU2015367307B2 (en) | Infant nutrition with hydrolysed protein and palmitic acid | |
JP2006022068A (ja) | 血清脂質代謝改善剤 | |
TWI761523B (zh) | 營養組成物 | |
TWI712367B (zh) | 營養組成物 | |
JP6439681B2 (ja) | 半固形状高栄養食品 | |
TW201822640A (zh) | 包含麥芽三糖之組成物,及使用彼以抑制由脫水方法導致之傷害的方法 | |
TW201247112A (en) | Infant formula for use in the prevention of cardiovascular diseases | |
MXPA06001894A (en) | Calcium fortified soy based infant nutritional formulas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20190724 Address after: Vevey Patentee after: SOCIETE DES PRODUITS NESTLE S. A. Address before: Vevey Patentee before: Nestle Products Technical Assistance Co., Ltd. |